ALRT's Oral Lekemia Drug Effective

26 May 1996

Interim results from a Phase I/II trial of Allergan Ligand Retinoid Therapeutics' 9-cis-retinoic acid product, ALRT1057, have revealed that six out of 15 patients with acute promyelocytic leukemia had complete remissions after treatment with the drug.

ALRT1057 was given once-daily at doses ranging from 30mg/m2 to 250mg/m2. The responding patients have remained in remission for durations of two to 18 months, notes the firm. Three of the six were newly-diagnosed APL patients, while three had relapsed after prior treatment with either all-trans-retinoic acid or cytotoxic chemotherapy. ALRT now plans to begin a Phase II/III trial of the drug to support a New Drug Application.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight